Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
August 4, 2025 7:00 AM EDT$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023
VYJUVEK approved in Japan for the treatment of DEB patients from birth
Strong balance sheet, ending the quarter with $820.8 million in cash and investments
PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update.
With the approval of VYJUVEK in Europe and Japan, we are on the cusp... More
